Advances in Targeting Tumor Microenvironment for Immunotherapy

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Oct 18

PMID 39421736

Authors

Lugang Wang

Liubo Zhang

Zhen Zhang

Peng Wu

Yi Zhang

Xinfeng Chen

Affiliations

Soon will be listed here.

Abstract

The tumor microenvironment (TME) provides essential conditions for the occurrence, invasion, and spread of cancer cells. Initial research has uncovered immunosuppressive properties of the TME, which include low oxygen levels (hypoxia), acidic conditions (low pH), increased interstitial pressure, heightened permeability of tumor vasculature, and an inflammatory microenvironment. The presence of various immunosuppressive components leads to immune evasion and affects immunotherapy efficacy. This indicates the potential value of targeting the TME in cancer immunotherapy. Therefore, TME remodeling has become an effective method for enhancing host immune responses against tumors. In this study, we elaborate on the characteristics and composition of the TME and how it weakens immune surveillance and summarize targeted therapeutic strategies for regulating the TME.

Citing Articles

Harnessing antibody-mediated recognition of the intracellular proteome with T cell receptor-like specificity.

Haus-Cohen M, Reiter Y Front Immunol. 2024; 15():1486721.

PMID: 39650646 PMC: 11621052. DOI: 10.3389/fimmu.2024.1486721.

References

Wang L, Luo Y, Ren S, Zhang Z, Xiong A, Su C . A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC. J Thorac Oncol. 2023; 19(3):465-475. DOI: 10.1016/j.jtho.2023.10.014. View

Naqash A, McCallen J, Mi E, Iivanainen S, Marie M, Gramenitskaya D . Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer. J Immunother Cancer. 2023; 11(10). PMC: 10603340. DOI: 10.1136/jitc-2023-007310. View

Zhang Y, Zhao Y, Shen J, Sun X, Liu Y, Liu H . Nanoenabled Modulation of Acidic Tumor Microenvironment Reverses Anergy of Infiltrating T Cells and Potentiates Anti-PD-1 Therapy. Nano Lett. 2019; 19(5):2774-2783. DOI: 10.1021/acs.nanolett.8b04296. View

Choueiri T, Bauer T, Papadopoulos K, Plimack E, Merchan J, Mcdermott D . Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med. 2021; 27(5):802-805. PMC: 9128828. DOI: 10.1038/s41591-021-01324-7. View

Lian B, Yan S, Li J, Bai Z, Li J . HNRNPC promotes collagen fiber alignment and immune evasion in breast cancer via activation of the VIRMA-mediated TFAP2A/DDR1 axis. Mol Med. 2023; 29(1):103. PMC: 10394847. DOI: 10.1186/s10020-023-00696-5. View

Xu R, Zhang Y, Pan H, Feng J, Zhang T, Liu T . Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021; 6(12):1015-1024. DOI: 10.1016/S2468-1253(21)00313-7. View

Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J . Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 B cell tumors: a phase 1/2 trial. Nat Med. 2024; 30(3):772-784. PMC: 10957466. DOI: 10.1038/s41591-023-02785-8. View

Boulch M, Cazaux M, Cuffel A, Guerin M, Garcia Z, Alonso R . Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4 CAR T-cell antitumor activity. Nat Cancer. 2023; 4(7):968-983. PMC: 10368531. DOI: 10.1038/s43018-023-00570-7. View

Davis E, Martin-Liberal J, Kristeleit R, Cho D, Blagden S, Berthold D . First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors. J Immunother Cancer. 2022; 10(10). PMC: 9628691. DOI: 10.1136/jitc-2021-004235. View

10.

Guo Y, Xie Y, Gao M, Zhao Y, Franco F, Wenes M . Metabolic reprogramming of terminally exhausted CD8 T cells by IL-10 enhances anti-tumor immunity. Nat Immunol. 2021; 22(6):746-756. PMC: 7610876. DOI: 10.1038/s41590-021-00940-2. View

11.

Bailey C, Liu Y, Liu M, Du X, Devenport M, Zheng P . Targeting HIF-1α abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues. J Clin Invest. 2022; 132(9). PMC: 9057613. DOI: 10.1172/JCI150846. View

12.

Baruch E, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L . Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2020; 371(6529):602-609. DOI: 10.1126/science.abb5920. View

13.

Ping Y, Shan J, Qin H, Li F, Qu J, Guo R . PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8 T cell ferroptosis. Immunity. 2024; 57(9):2122-2139.e9. DOI: 10.1016/j.immuni.2024.08.003. View

14.

Preston S, Bartish M, Richard V, Aghigh A, Goncalves C, Smith-Voudouris J . Phosphorylation of eIF4E in the stroma drives the production and spatial organisation of collagen type I in the mammary gland. Matrix Biol. 2022; 111:264-288. DOI: 10.1016/j.matbio.2022.07.003. View

15.

Huang Y, Yuan J, Righi E, Kamoun W, Ancukiewicz M, Nezivar J . Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012; 109(43):17561-6. PMC: 3491458. DOI: 10.1073/pnas.1215397109. View

16.

Lee E, Zhang P, Wen P, Gerstner E, Reardon D, Aldape K . NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer. 2020; 126(12):2821-2828. PMC: 7245544. DOI: 10.1002/cncr.32811. View

17.

Gao F, Li X, Xu K, Wang R, Guan X . c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment. Cell Commun Signal. 2023; 21(1):28. PMC: 9887805. DOI: 10.1186/s12964-023-01043-1. View

18.

Watson M, Vignali P, Mullett S, Overacre-Delgoffe A, Peralta R, Grebinoski S . Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 2021; 591(7851):645-651. PMC: 7990682. DOI: 10.1038/s41586-020-03045-2. View

19.

Yang M, Qin C, Tao L, Cheng G, Li J, Lv F . Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment. Biomaterials. 2023; 301:122253. DOI: 10.1016/j.biomaterials.2023.122253. View

20.

Zanvit P, van Dyk D, Fazenbaker C, McGlinchey K, Luo W, Pezold J . Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer. J Clin Invest. 2023; 133(22). PMC: 10645390. DOI: 10.1172/JCI169655. View